Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael Kreuter"'
Autor:
Manuela, Funke-Chambour, Carlo, Albera, Elisabeth, Bendstrup, Ulrich, Costabel, Jan C, Grutters, Sergio, Harari, Kerri A, Johannson, Michael, Kreuter, Irina, Strambu, Carlo, Vancheri, Francesco, Varone, Patrizio, Vitulo, Wim A, Wuyts, Fernando, Martinez, Ganesh, Raghu, Wim, Wuyts
Publikováno v:
Funke-Chambour, M, Albera, C, Bendstrup, E, Costabel, U, Grutters, J C, Harari, S, Johannson, K A, Kreuter, M, Strambu, I, Vancheri, C, Varone, F, Vitulo, P, Wuyts, W A, Martinez, F & Raghu, G 2021, ' Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis : Results of a Delphi survey ', European Respiratory Journal, vol. 57, no. 4, 2004219 . https://doi.org/10.1183/13993003.04219-2020
Medical guidelines on diagnosis and management of relevant diseases aim to recommend clinical practice while standardising patient care. However, evidence-based guideline development is laborious and challenging, the recommendations require nuanced w
Autor:
Sabrina Bajwah, Athol U. Wells, Polly Edmonds, Steffen T. Simon, Irene J Higginson, Richard P Towers, Michael Kreuter, David C. Currow, Surinder S. Birring, Miriam J. Johnson, Andrew Wilcock, Wendy Prentice, Elisabeth Bendstrup, Claudia Bausewein, Massimo Costantini
Publikováno v:
Bajwah, S, Wilcock, A, Towers, R, Costantini, M, Bausewein, C, Simon, S T, Bendstrup, E, Prentice, W, Johnson, M J, Currow, D C, Kreuter, M, Wells, A U, Birring, S S, Edmonds, P & Higginson, I J 2020, ' Managing the supportive care needs of those affected by COVID-19 ', The European Respiratory Journal, vol. 55, no. 4, 2000815 . https://doi.org/10.1183/13993003.00815-2020
Globally, the number of people affected by coronavirus disease 2019 (COVID-19) is rapidly increasing. In most (>80%), the illness is relatively mild and can be self-managed out of hospital. However, in about 20% the illness causes respiratory comprom
Autor:
Derek Weycker, Nicolas Kahn, Klaus-Uwe Kirchgaessler, Carlo Vancheri, Mark Atwood, Brett Ley, Michael Kreuter, Christopher J. Ryerson, David J. Lederer, Vincent Cottin
Publikováno v:
The European Respiratory Journal
Patients with idiopathic pulmonary fibrosis (IPF) frequently have a substantial burden of comorbidities [1]. Antifibrotic therapy is recommended to slow the progression of IPF [2]. Patients receiving antifibrotic therapy frequently receive concomitan
Autor:
Jochen Wilhelm, Horst Olschewski, Ralph T. Schermuly, Lukasz Wujak, Leigh M. Marsh, Grazyna Kwapiszewska, Miroslava Didiasova, Anna Gungl, Malgorzata Wygrecka, Andrea Olschewski, Benjamin P. Weiss, Djuro Kosanovic, Liliana Schaefer, Katharina Sinn, Helene Thekkekara Puthenparampil, Michael Kreuter, Marc A. Schneider, Werner Seeger, Walter Klepetko
Publikováno v:
The European respiratory journal. 52(5)
Despite the beneficial effects of pirfenidone in treating idiopathic pulmonary fibrosis (IPF), it remains unclear if lung fibroblasts (FB) are the main therapeutic target.To resolve this question, we employed a comparative transcriptomic approach and